This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding This event will be broadcast live on Friday, June 23, 2023, from 12:00 p.m. We use Zoom technology for this webinar.
HPM) Director Dara Katcher Levy will present an informative webinar on the newly released AMCP Format for Formulary Submissions version 5.0. To register for this insightful webinar, visit AMCP Learn. This afternoon Hyman, Phelps & McNamara, P.C.
In recent years, each of these companies has launched new group purchasing organizations (GPOs) to further consolidate the number of covered lives in rebate negotiations with pharmaceuticalmanufacturers. Today, I examine these PBM-owned GPOs and then speculate on five plausible explanations for their existence. to 1:30 p.m.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Time for Drug Channels ’ annual update on pricing at the largest pharmaceuticalmanufacturers. Click here to see the original post from May 2022.
Time for Drug Channels ’ annual update on pricing at the largest pharmaceuticalmanufacturers. Learn about the future of these programs during my upcoming live video webinar, PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding , on June 23, 2023, from 12:00 p.m. to 1:30 p.m.
In this GEP webinar with Procurement Leaders — Partnering Through a Time of Transformation — Joel Johnson, VP, GEP shares insights on building enduring relationships with your suppliers and managing them for long-term success. BST / 10 a.m.
This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. As you reread the article below, note that some manufacturers have already announced wholesale acquisition cost (WAC) list price declines for 2025. Click here to see the original post.
Webinars – Webinars, whether live streamed or on-demand, can be used for communication with HCPs, HCOs, and POs. A company is responsible for the content of webinars and should take reasonable steps to ensure the audience is targeted and well defined.
At the same time, Viseven never misses an opportunity to share our findings and insights with colleagues and clients in our blogs, during live webinar sessions with top industry experts, and, of course, at global events. Top Publications and Webinars of the Year. Both webinars can be viewed on our YouTube page.
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Update: 340B Controversies and Outlook. Time for Drug Channels ' annual update on pricing at six of the largest pharmaceuticalmanufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi.
Tablet manufacturing, which is the most common OSD form, takes an API dry powder ingredient and compresses it to form tablets, which can be coated or uncoated. Compared to other dosage forms, tablets are simpler to manufacture, package, and transport. Please check your email to download the Webinar.
Want to bundle the report with DCIs video webinars ? You can pay online using Visa, MasterCard, American Express, Discover, and PayPal. If you prefer to pay by corporate check or ACH, click here to request an invoice. Email Paula Fein ( paula@drugchannels.net ). Didnt get it? Contact us at dcisupport@hmpglobal.com, and well take care of it.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content